[1] McKinnon E,Xiao P.Metaplastic carcinoma of the breast[J].Arch Pathol Lab Med,2015,139(6):819-822.

[2] Paul Wright G,Davis AT,Koehler TJ,et al.Hormone receptorstatus does not affect prognosis in metaplastic breast cancer: a population-based analysis with comparison to infiltrating ductal and lobular carcinomas[J].Ann Surg Oncol,2014,21(11):3497-3503.

[3] Shah DR, Tseng WH, Martinez SR.Treatment options for metaplastic breast cancer[J]. ISRN Oncol,2012,2012:706162.

[4] Hu Q,Chen WX,Zhong SL,et al.Current progress in the treatment of metaplastic breast carcinoma[J]. Asian Pac J Cancer Prev,2013,14(11):6221-6225.

[5] Luini A,Aguilar M,Gatti G,et al.Metaplastic carcinoma of the breast, an unusual disease with worse prognosis: the experience of the European Institute of Oncology and review of the literature[J].Breast Cancer Res Treat,2007,101(3):349-353.

[6] Terando AM, Agnese DM, Holmes DR.Treatment and Prognosis of Rare Breast Cancers[J]. Ann Surg Oncol,2015,22(10):3225-3229.

[7] Lakhani SR,Ellis IO,Schnitt SJ,et al.WHO Classification of Tumours of the breast[M].4th ed.Lyon:IARC Press,2012:48-54.

[8] Nowara E,Drosik A,Samborska-Plewicka M,et al.Metaplastic breast carcinomas-analysis of prognostic factors in a case series[J]. Contemp Oncol(Pozn),2014,18(2):116-119.

[9] 肖 盟,赵洪猛,杨正军,等.乳腺化生性癌的临床病理特征及预后影响因素[J].中国肿瘤临床,2015,42(12):614-619.

[10] Barr JG, Jane Clayton ES, Sotheran W.A case of metaplastic breast cancer in a man[J].J Surg Case Rep, 2013,2013(2).dio:10.1093/jscr/rjs047.

[11] Oon ML,Thike AA,Tan SY,et al.Cancer stem cell and epithelial-mesenchymal transition markers predict worse outcome in metaplastic carcinoma of the breast[J].Breast Cancer Res Treat,2015 ,150(1):31-41.

[12] Abd El Hafez A, Shawky Ael-A.Analysis of metaplastic breast carcinoma: FNAC;histopathology and immunohistochemistry are complementary for diagnosis[J].Breast Dis,2013,34(2):67-75.

[13] Altaf FJ, Mokhtar GA,Emam E,et al. Metaplastic carcinoma of the breast: an immunohistochemical study[J]. Diagn Pathol,2014,9:139.

[14] Rungta S,Kleer CG.Metaplastic carcinomas of the breast: diagnostic challenges and new translational insights[J]. Arch Pathol Lab Med,2012,136(8): 896-900.

[15] Schwartz TL,Mogal H,Papageorgiou C,et al.Metaplasticbreast cancer: histologic characteristics, prognostic factors and systemic treatment strategies[J]. Exp Hematol Oncol,2013,2(1):31.

[16] Esbah O,Turkoz FP,Turker I,et al.Metaplastic breast carcinoma: case series and review of the literature[J].Asian Pac J Cancer Prev,2012,13(9):4645-4649.

[17] Pezzi CM,Patel-Parekh L,Cole K,et al.Characteristics and treatment of metaplastic breast cancer:analysis of 892 cases from the National Cancer Data Base[J].Ann Surg Oncol,2007,14(1):166-173.

[18] Lai YC,Hsu CY,Chou YH,et al.Sonographic presentations of metaplastic breast cancers[J].J Chin Med Assoc,2012,75(11):589-594.

[19] Choi BB, Shu KS.Metaplastic carcinoma of the breast: multimodality imaging and histopathologic assessment[J].Acta Radiol,2012,53(1):5-11.

[20] Wang H, Guan B, Shi Q, et al.May metaplastic breastcarcinomas be actually basal-like carcinoma? Further evidence study with its ultrastructure and survival analysis[J]. Med Oncol,2011,28(1):42-50.

[21] Moulder S, Moroney J, Helgason T,et al. Responses to liposomal Doxorubicin, bevacizumab, and temsirolimus in metaplastic carcinoma of the breast: biologic rationale and implications for stem-cell research in breast cancer[J]. J Clin Oncol, 2011,29(19):42-50.

[22] Dave G,Cosmatos H,Do T,et al.Metaplastic carcinoma of the breast: a retrospective review[J].Int J Radiat Oncol Biol Phys,2006,64(3):771-775.

[23] 丁彩霞,黄颖楠,冯海波,等.乳腺化生性癌8 例临床病理分析[J].现代肿瘤医学,2014,22(9):2123-2127.

[24] Zhang Y,Lv F,Yang Y,et al.Clinicopathological features and prognosis of metaplastic breast carcinoma: Experience of a major chinese cancer center[J]. PLoS One,2015,10(6):e0131409.

[25] Leibl S,Moinfar F.Metaplastic breast carcinomas are negative for Her-2 but frequently express EGFR (Her-1): potential relevance to adjuvant treatment with EGFR tyrosine kinase inhibitors?[J].J Clin Pathol,2005,58(7):700-704.

[26] Nelson RA,Guye ML,Luu T,et al.Survival outcomes of metaplastic breast cancer patients: results from a US population-based analysis[J].Ann Surg Oncol,2015,22(1):24-31.

[27] Tseng WH,Martinez SR.Metaplastic breast cancer: to radiate or not to radiate? [J].Ann Surg Oncol,2011,18(1):94-103.

[28] Rakha EA, Tan PH, Varga Z,et al. Prognostic factors in metaplastic carcinoma of the breast: a multi-institutional study[J]. Br J Cancer,2015 ,112(2):283-289.

[29] Chen IC,Lin CH,Huang CS,et al.Lack of efficacy to systemic chemotherapy for treatment of metaplastic carcinoma of the breast in the modern era[J].Breast Cancer Res Treat,2011,130(1):345-351.

[30] Cooper CL,Karim RZ,Selinger C,et al.Molecular alterations in metaplastic breast carcinoma[J].J Clin Pathol,2013,66(6):522-528.

[31] 尚文博,张丽娜,李春晓,等. 化生性乳腺癌23例临床分析[J]. 中华普通外科杂志,2013,28(10):799-800.

[32] Lee H,Jung SY,Ro JY,et al.Metaplastic breast cancer:clinicopathological features and its prognosis[J].J Clin Pathol,2012,65(5):441-446.

[33] Aydiner A, Sen F, Tambas M,et al.Metaplastic breast carcinoma versus triple-negative breast cancer: survival and response to treatment[J].Medicine (Baltimore), 2015,94(52):e2341.

[34] Mallini P, Lennard T, Kirby J,et al.Epithelial-to-mesenchymal transition:what is the impact on breast cancer stem cells and drug resistance[J].Cancer Treat Rev,2014,40(3):341-348.

[35] Choi Y, Lee HJ, Jang MH,et al.Epithelial-mesenchymal transition increases during the progression of in situ to invasive basal-like breast cancer[J]. Hum Pathol,2013,44(11):2581-2589.

[36] Okada N,Hasebe T,Iwasaki M,et al.Metaplastic carcinoma of the breast[J].Hum Pathol,2010,41(7):960-970.

[37] Weigelt B, Eberle C, Cowell CF, et al. Metaplastic breast carcinoma: more than a special type[J]. Nat Rev Cancer, 2014,14(3):147-148.

[38] Zhang Y, Toy KA, Kleer CG. Metaplastic breast carcinomas are enriched in markers of tumor-initiating cells and epithelial to mesenchymal transition[J].Mod Pathol,2012,25(2):178-184.